Literature DB >> 6171573

Influence of human leukocyte interferon on squamous cell carcinoma of uterine cervix: clinical, histological, and histochemical observations. III. Communication.

J Krusić, V Kirhmajer, M Knezević, D Ikić, Z Maricić, B Rode, D Jusić, E Soos.   

Abstract

Fifteen patients with invasive squamous cell carcinoma of the uterine cervix were treated with human leukocyte interferon (HLI). HLI was applied topically and i.m. to nine patients, and only topically to six. After therapy, surgical material was free from tumor cells in three patients, tumor cells were identified as invasive carcinoma in one patient and as CA in situ in two patients. Findings remained unchanged in nine patients. Tumor metastases in the lymph nodes were found in only one patient. The patients' overall response to therapy was assessed on the basis of stromal response, relation of tumor cells and macrophage activity, and the reactivity of lymph nodes.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6171573     DOI: 10.1007/BF00410116

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  2 in total

1.  Radical hysterectomy and pelvic lymphadenectomy for carcinoma of the uterine cervix.

Authors:  A S Ketcham; R C Hoye; P T Taylor; P J Deckers; L B Thomas; P B Chretien
Journal:  Cancer       Date:  1971-11       Impact factor: 6.860

2.  Carcinoma of the uterine cervix. A study of 864 patients.

Authors:  I C Nielson; R R Smith; J R McLaren; J E Scarborough
Journal:  Cancer       Date:  1967-01       Impact factor: 6.860

  2 in total
  1 in total

1.  Safety and preliminary efficacy data of a novel casein kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies.

Authors:  Ana M Solares; Agueda Santana; Idania Baladrón; Carmen Valenzuela; Carlos A González; Alina Díaz; Dagnelia Castillo; Thelvia Ramos; Roberto Gómez; Daniel F Alonso; Luis Herrera; Hugo Sigman; Silvio E Perea; Boris E Acevedo; Pedro López-Saura
Journal:  BMC Cancer       Date:  2009-05-13       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.